Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands
This article was originally published in The Pink Sheet Daily
Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.
You may also be interested in...
The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.
The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.
Elcelyx spins out new company to advance weight-loss supplement while it focuses on delayed-release metformin for type 2 diabetes. Also, Medivir announces promising data for a combination of HCV drugs in patients with advanced fibrosis or cirrhosis of the liver, while Repligen has earned its first milestone under a collaboration in spinal muscular atrophy with Pfizer.